文献速递银屑病与炎症性皮肤病药疹与重症皮肤不良反应

免疫检查点抑制剂介导的银屑病:欧洲多中心115例研究

Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group.
PubMed 文献 · J Am Acad Dermatol · 2020-12-03

该多中心回顾性研究纳入115例免疫检查点抑制剂(ICI)介导的银屑病患者,发现多数为1级严重度,阿维A是最常用系统治疗;基线体表面积>10%与ICI治疗调整及永久停药风险增加相关,多数患者可完成ICI治疗。

要点

  • ICI介导银屑病多为轻中度,阿维A、阿普斯特和甲氨蝶呤是安全有效的系统治疗选择。
  • 基线体表面积>10%提示ICI治疗调整或永久停药风险增高。
  • 多数患者可顺利完成ICI治疗,无需因银屑病永久停药。

核心结论

  • 阿维A、阿普斯特和甲氨蝶呤是ICI介导银屑病安全有效的治疗方式,多数患者可顺利完成ICI治疗。

研究设计与样本

  • 回顾性多中心研究,纳入9家机构的115例ICI介导银屑病患者。

主要发现

  • 1级、2级和3级疾病严重度分别为60/105(57.1%)、34/105(32.4%)和11/105(10.5%)。
  • 加重与新生病例比为1:4.3。
  • 最常用系统治疗为阿维A(23例,20.1%),其次为系统激素(8例,7%)、阿普斯特(7例,6.1%)、甲氨蝶呤(5例,4.3%)和生物制剂(4例,3.6%)。
  • 29/112例(25.9%)因银屑病中断ICI,20/111例(18%)永久停用ICI。

临床怎么用

  • 对ICI介导银屑病可选用阿维A、阿普斯特或甲氨蝶呤进行系统治疗。
  • 基线体表面积>10%的患者需警惕ICI治疗调整或永久停药风险。
  • 多数患者无需因银屑病中断ICI治疗,可参考提出的阶梯管理算法。

局限性

  • 回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitor (ICI)-mediated psoriasis poses significant diagnostic and therapeutic challenges. OBJECTIVE: To report data on ICI-mediated psoriasis, emerging from the largest cohort to date, to our knowledge, and to propose a step-by-step management algorithm. METHODS: The medical records of all patients with ICI-mediated psoriasis were retrospectively reviewed across 9 institutions. RESULTS: We included a cohort of 115 individuals. Grade 1, 2, and 3 disease severity was reported in 60 of 105 (57.1%, 10 missing data), 34 of 105 (32.4%), and 11 of 105 (10.5%), respectively. The ratio between exacerbation and de novo cases was 1:4.3. The most common systemic therapy was acitretin (23 patients, 20.1%), followed by systemic steroids (8 patients, 7%), apremilast (7 patients, 6.1%), methotrexate (5 patients, 4.3%) and biologics (4 patients, 3.6%). Overall, 29 of 112 patients (25.9%) interrupted and 20 of 111 (18%) permanently discontinued ICIs because of psoriasis. Body surface area of greater than 10% at baseline had a 3.6 increased risk for ICI treatment modification (odds ratio, 3.64; 95% confidence interval, 1.27-10.45; P = .03) and a 6.4 increased risk for permanent discontinuation (odds ratio, 6.41; 95% confidence interval, 2.40-17.11; P < .001). Guttate psoriasis and grade 2 or 3 disease were significant positive predictors for antitumor response of ICI, whereas pruritus was a negative predictor. LIMITATIONS: Retrospective design. CONCLUSION: Acitretin, apremilast, and methotrexate are safe and effective modalities for ICI-mediated psoriasis. In most cases, ICI can be completed unhindered. A therapeutic algorithm is proposed.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Nikolaou V, Sibaud V, Fattore D, et al. Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group. J Am Acad Dermatol. 2020. PMID: 33279646. doi:10.1016/j.jaad.2020.08.137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。